Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Early results demonstrate near-complete elimination of tricuspid regurgitation in implanted patients with favorable safety profile and no permanent pacemaker implantations Paris, France and Munich,...
-
Early results demonstrate near-complete elimination of tricuspid regurgitation in implanted patients with favorable safety profile and no permanent pacemaker implantations Paris, France and Munich,...
-
Paris, France and Munich, Germany, January 09, 2025 – TRiCares SAS (“TRiCares”), a company pioneering a minimally-invasive tricuspid valve that flexes with every heartbeat, announces that the first...
-
TRiCares Announces First Topaz Implantation in EU Pivotal StudyParis, France and Munich, Germany, September 24, 2024 – TRiCares SAS (“TRiCares”), a company pioneering a minimally-invasive tricuspid...
-
TRiCares Raises $50m in Series D Financing to Support Upcoming Clinical Milestones Paris, France and Munich, Germany, July 25, 2024 – TRiCares SAS (“TRiCares”), a privately held pioneer in the field...
-
PRESS RELEASE Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a...
-
TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker Paris, France and Munich, Germany, December 21, 2023 –...
-
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich,...
-
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, September...
-
TRiCares schließt eine Finanzierungsrunde der Serie B in Höhe von € 22 Millionen ($ 25,4 Millionen) zur Investition in die Entwicklung einer minimal invasiven Behandlung von Trikuspidal-Insuffizienz ...